2.4.1.62: ganglioside galactosyltransferase
This is an abbreviated version!
For detailed information about ganglioside galactosyltransferase, go to the full flat file.
Reaction
+
=
+
Synonyms
B3GALT4, beta 1,3-galactosyltransferase, beta3Gal-T, ceramide galactosyltransferase, ceramide galactosyltransferase UGT8, CGT, CgtB 11168, cgtBOH HS:10, cgtBOH4384, GA1/GM1/GD1b synthase, Gal-T2, galactosyltransferase, uridine diphosphogalactose-ceramide, GALT, GalT-3, GM1-synthase, UDP galactose-LAC Tet-ceramide alpha-galactosyltransferase, UDP-galactose-ceramide galactosyltransferase, UDP-galactose-GM2 galactosyltransferase, UDP-galactose-GM2 ganglioside galactosyltransferase, UDP-galactose:beta-N-acetylglucosamine beta-1,3-galactosyltransferase, UDP-galactose:ceramide galactosyltransferase, UDP-galactose:GM2 ganglioside beta1-3 galactosyltransferase, UDP-galactose:N-acetylgalactosaminyl-(N-acetylneuraminyl) galactosyl-glucosyl-ceramide galactosyltransferase, uridine diphosphate D-galactose:glycolipid galactosyltransferase, uridine diphosphogalactose-ceramide galactosyltransferase, uridine diphosphogalactose-GM2 galactosyltransferase
ECTree
Engineering
Engineering on EC 2.4.1.62 - ganglioside galactosyltransferase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DELTA20C
mutant with deletion of 20 amino acids from carboxy terminus + C-terminal MalE fusion, specific activity (mU/mg): 58.1 (substrate: GalNAcalpha), 127.5 (substrate: GalNAcbeta), 17.5 (substrate: GM2), 374 (substrate: GA2)
DELTA20N
mutant with deletion of 20 amino acids from carboxy terminus + N-terminal MalE fusion, specific activity (mU/mg): 3.3 (substrate: GalNAcalpha), 8.0 (substrate: GalNAcbeta), 2.3 (substrate: GM2), 34.4 (substrate: GA2)
D175A
overexpression of the mutant and -D291A does not rescue galactosylation deficiency of a knockout strain
D176A
overexpression of the mutant and -D291A does not rescue galactosylation deficiency of a knockout strain
D177A
overexpression of the mutant and -D291A does not rescue galactosylation deficiency of a knockout strain
DELTA30C
mutant with deletion of 30 amino acids from carboxy terminus + C-terminal MalE fusion, specific activity (mU/mg): 11.6 (substrate: GalNAcalpha), 75.7 (substrate: GalNAcbeta), 80.9 (substrate: GM2)
DELTA30C
mutant with deletion of 30 amino acids from carboxy terminus + C-terminal MalE fusion, specific activity (mU/mg): 531.5 (substrate: GalNAcalpha), 1299.5 (substrate: GalNAcbeta), 2420 (substrate: GM2), 271.5 (substrate: IFNalpha2b). kcat (1/sec): 0.5 (GalNAcalpha-FCHASE), 1.07 (GalNAcbeta-FCHASE), 0.05 (UDP-Gal), Km (mM): 1.68 (GalNAcalpha-FCHASE), 3.18 (GalNAcbeta-FCHASE), 1.11 (UDP-Gal)
DELTA30N
mutant with deletion of 30 amino acids from carboxy terminus + N-terminal MalE fusion, specific activity (mU/mg): 0.9 (substrate: GalNAcalpha), 5.3 (substrate: GalNAcbeta), 14 (substrate: GM2)
DELTA30N
mutant with deletion of 30 amino acids from carboxy terminus + N-terminal MalE fusion, specific activity (mU/mg): 49.5 (substrate: GalNAcalpha), 36 (substrate: GalNAcbeta), 96 (substrate: GM2), 14 (substrate: IFNalpha2b)
additional information
point mutation at the glycosylation site results in loss of activity and enzyme targeting to the endoplasmic reticulum instead of the Golgi apparatus
additional information
-
point mutation at the glycosylation site results in loss of activity and enzyme targeting to the endoplasmic reticulum instead of the Golgi apparatus
additional information
-
Cgt-/-, Cgt deficient mice, no accumulation of galactolipids, increased ceramide levels